Figure 3
From: Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma
miR-181b could reverse EMT by targeting KPNA4 and its expression correlates with better prognosis.
(A) In the TCGA and CGGA cohorts and another independent cohort, patients with elevated miR-181b expression had a better prognosis (p = 0.008, p = 0.023 and p < 0.0001, respectively). (B) Diagram of the seed sequence of miR-181b matching the 3′UTRs of the KPNA4 gene and the design of wild-type or mutant KPNA4 3′UTR-containing reporter constructs. (C) Luciferase reporter assays in glioma cells after co-transfection of cells with wild-type or mutant 3′UTR KPNA and miR-181b. The data represent the fold change in the expression (mean ± SE) of 3 replicates. *p < 0.05. (D) Western blot for KPNA4, N-cadherin, E-cadherin and Vimentin expression 48 hours after transfection with miR-NC or miR-181b. (E) Immunohistochemisty revealed that tumors in the miR-181b low expression group had lower KPNA4, N-cadherin and Vimentin and higher E-cadherin expression.
